☰

Timothy D. Owens, Ph.D. - Publications

Affiliations: 
2002 University of California, Berkeley, Berkeley, CA, United States 
Area:
chemical synthesis
Tree Info Similar researchers PubMed Report error

9/34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2003 Owens TD, Souers AJ, Ellman JA. The preparation and utility of bis(sulfinyl)imidoamidine ligands for the copper-catalyzed Diels-Alder reaction. The Journal of Organic Chemistry. 68: 3-10. PMID 12515453 DOI: 10.1021/Jo020524C  0.647
2002 Ellman JA, Owens TD, Tang TP. N-tert-butanesulfinyl imines: versatile intermediates for the asymmetric synthesis of amines. Accounts of Chemical Research. 35: 984-95. PMID 12437323 DOI: 10.1021/Ar020066U  0.636
2001 Owens TD, Semple JE. Atom-economical synthesis of the N(10)-C(17) fragment of cyclotheonamides via a novel Passerini reaction-deprotection-acyl migration strategy. Organic Letters. 3: 3301-4. PMID 11594819 DOI: 10.1021/ol0165239  0.404
2001 Souers AJ, Owens TD, Oliver AG, Hollander FJ, Ellman JA. Synthesis and crystal structure of a unique and homochiral N,S-bonded N,N'-bis(tert-butanesulfinyl)amidinate rhodium(I) complex. Inorganic Chemistry. 40: 5299-301. PMID 11559098 DOI: 10.1021/Ic0104205  0.64
2001 Owens TD, Hollander FJ, Oliver AG, Ellman JA. Synthesis, utility, and structure of novel bis(sulfinyl)imidoamidine ligands for asymmetric Lewis acid catalysis [21] Journal of the American Chemical Society. 123: 1539-1540. DOI: 10.1021/Ja005635C  0.635
2001 Owens TD, Araldi GL, Nutt RF, Semple JE. Concise total synthesis of the prolyl endopeptidase inhibitor eurystatin A via a novel Passerini reaction-deprotection-acyl migration strategy Tetrahedron Letters. 42: 6271-6274. DOI: 10.1016/S0040-4039(01)01287-4  0.435
2000 Semple JE, Owens TD, Nguyen K, Levy OE. New synthetic technology for efficient construction of alpha-hydroxy-beta-amino amides via the Passerini reaction. Organic Letters. 2: 2769-72. PMID 10964361 DOI: 10.1021/Ol0061485  0.484
1999 Liu G, Cogan DA, Owens TD, Tang TP, Ellman JA. Synthesis of enantiomerically pure N-tert-butanesulfinyl imines (tert- butanesulfinimines) by the direct condensation of tert-butanesulfinamide with aldehydes and ketones Journal of Organic Chemistry. 64: 1278-1284. DOI: 10.1021/Jo982059I  0.637
1998 Owens TD, Semple JE. Alkoxide-catalyzed ring-opening of a novel homosaccharin derivative: synthesis of potent, selective P3-lactam thrombin inhibitors containing P4-o-alkoxycarbonylbenzylsulfonamide residues. Bioorganic & Medicinal Chemistry Letters. 8: 3683-8. PMID 9934495 DOI: 10.1016/S0960-894X(98)00667-2  0.368
Low-probability matches (unlikely to be authored by this person)
2000 Semple JE, Levy OE, Minami NK, Owens TD, Siev DV. Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic P1-ketoamide moieties. Bioorganic & Medicinal Chemistry Letters. 10: 2305-9. PMID 11055344 DOI: 10.1016/S0960-894X(00)00458-3  0.28
2001 Semple JE, Owens TD, Nguyen K, Levy OE. ChemInform Abstract: New Synthetic Technology for Efficient Construction of α-Hydroxy-β-amino Amides via the Passerini Reaction. Cheminform. 32: no-no. DOI: 10.1002/chin.200102082  0.21
2015 Lou Y, Sweeney ZK, Kuglstatter A, Davis D, Goldstein DM, Han X, Hong J, Kocer B, Kondru RK, Litman R, McIntosh J, Sarma K, Suh J, Taygerly J, Owens TD. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold. Bioorganic & Medicinal Chemistry Letters. 25: 367-71. PMID 25466710 DOI: 10.1016/j.bmcl.2014.11.030  0.183
1996 Semple JE, Rowley DC, Brunck TK, Ha-Uong T, Minami NK, Owens TD, Tamura SY, Goldman EA, Siev DV, Ardecky RJ, Carpenter SH, Ge Y, Richard BM, Nolan TG, HÃ¥kanson K, et al. Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties. Journal of Medicinal Chemistry. 39: 4531-6. PMID 8917639 DOI: 10.1021/jm960572n  0.165
1998 Semple JE, Rowley DC, Owens TD, Minami NK, Uong TH, Brunck TK. Potent and selective thrombin inhibitors featuring hydrophobic, basic P3-P4-aminoalkyllactam moieties. Bioorganic & Medicinal Chemistry Letters. 8: 3525-30. PMID 9934465 DOI: 10.1016/S0960-894X(98)00636-2  0.139
2015 Lou Y, Han X, Kuglstatter A, Kondru RK, Sweeney ZK, Soth M, McIntosh J, Litman R, Suh J, Kocer B, Davis D, Park J, Frauchiger S, Dewdney N, Zecic H, ... ... Owens TD, et al. Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. Journal of Medicinal Chemistry. 58: 512-6. PMID 24712864 DOI: 10.1021/jm500305p  0.124
2016 Lou Y, Lopez F, Jiang Y, Han X, Brotherton C, Billedeau R, Gabriel S, Gleason S, Goldstein DM, Hilgenkamp R, Kocer B, Orzechowski L, Tan J, Wovkulich P, Wen B, ... ... Owens TD, et al. Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK). Bioorganic & Medicinal Chemistry Letters. PMID 28025004 DOI: 10.1016/j.bmcl.2016.11.092  0.12
2021 Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, Hartmann S, Francesco MR, Langrish CL, Nunn PA, Gourlay SG. Phase 1 Clinical Trial Evaluating Safety, Exposure and Pharmacodynamics of BTK Inhibitor Tolebrutinib (PRN2246, SAR442168). Clinical and Translational Science. PMID 34724345 DOI: 10.1111/cts.13162  0.12
2017 Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung KH, Shu J, LaStant J, Loughhead DG, Karr DE, Gerritsen ME, Goldstein DM, Funk JO. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. PMID 28665128 DOI: 10.1021/acs.jmedchem.7b00360  0.109
2013 Padilla F, Bhagirath N, Chen S, Chiao E, Goldstein DM, Hermann JC, Hsu J, Kennedy-Smith JJ, Kuglstatter A, Liao C, Liu W, Lowrie LE, Luk KC, Lynch SM, Menke J, ... ... Owens TD, et al. Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. Journal of Medicinal Chemistry. 56: 1677-92. PMID 23350847 DOI: 10.1021/jm301720p  0.086
2012 Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D, Woods J, Levin A, O'Mahony A, Owens TD, et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. The Journal of Pharmacology and Experimental Therapeutics. 341: 90-103. PMID 22228807 DOI: 10.1124/Jpet.111.187740  0.079
2015 Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, et al. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. The Journal of Biological Chemistry. 290: 5960-78. PMID 25593320 DOI: 10.1074/Jbc.M114.614891  0.073
2018 Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. Embo Reports. PMID 30279279 DOI: 10.15252/embr.201846512  0.06
2022 Owens TD, Brameld KA, Verner EJ, Ton T, Li X, Zhu J, Masjedizadeh MR, Bradshaw JM, Hill RJ, Tam D, Bisconte A, Kim EO, Francesco M, Xing Y, Shu J, et al. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). Journal of Medicinal Chemistry. PMID 35302767 DOI: 10.1021/acs.jmedchem.1c01170  0.06
2017 Venetsanakos E, Brameld KA, Phan VT, Verner E, Owens TD, Xing Y, Tam D, LaStant J, Leung K, Karr DE, Hill RJ, Gerritsen ME, Goldstein DM, Funk JO, Bradshaw JM. The irreversible covalent fibroblast growth factor receptor inhibitor PRN1371 exhibits sustained inhibition of FGFR after drug clearance. Molecular Cancer Therapeutics. PMID 28978721 DOI: 10.1158/1535-7163.MCT-17-0309  0.058
2015 Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, ... ... Owens TD, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nature Chemical Biology. 11: 525-31. PMID 26006010 DOI: 10.1038/Nchembio.1817  0.056
2021 Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, LaStant J, Bisconte A, Outerbridge C, White SD, Hill RJ, Brameld KA, Goldstein DM, Nunn PA. Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. Journal of Immunology (Baltimore, Md. : 1950). PMID 33674445 DOI: 10.4049/jimmunol.2001130  0.056
2015 Hill R, Bradshaw J, Bisconte A, Tam D, Owens T, Brameld K, Smith P, Funk J, Goldstein D, Nunn P. THU0068 Preclinical Characterization of PRN1008, a Novel Reversible Covalent Inhibitor of BTK that Shows Efficacy in a RAT Model of Collagen-Induced Arthritis Annals of the Rheumatic Diseases. 74: 216.2-217. DOI: 10.1136/annrheumdis-2015-eular.3641  0.05
2012 Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. Journal of Medicinal Chemistry. 55: 4539-50. PMID 22394077 DOI: 10.1021/jm300035p  0.049
2022 Modrowski CA, Sheerin KM, Owens T, Pine SM, Shea LM, Frazier E, Lowenhaupt E. Piloting an Evidence-Based Assessment Protocol for Incarcerated Adolescents. Evidence-Based Practice in Child and Adolescent Mental Health. 8: 525-540. PMID 38144516 DOI: 10.1080/23794925.2022.2051216  0.048
2015 Cho HS, Shin HM, Haberstock-Debic H, Xing Y, Owens TD, Funk JO, Hill RJ, Bradshaw JM, Berg LJ. A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression. Journal of Immunology (Baltimore, Md. : 1950). PMID 26466958 DOI: 10.4049/Jimmunol.1501828  0.047
1997 Blinkova A, Burkart MF, Owens TD, Walker JR. Conservation of the Escherichia coli dnaX programmed ribosomal frameshift signal in Salmonella typhimurium. Journal of Bacteriology. 179: 4438-42. PMID 9209069 DOI: 10.1128/Jb.179.13.4438-4442.1997  0.036
2021 Fitzgerald M, Owens T, Moore J, Goldberg A, Lowenhaupt E, Barron C. Development of a Multi-Session Curriculum Addressing Domestic Minor Sex Trafficking for High-Risk Male Youth. Journal of Child Sexual Abuse. 1-17. PMID 34296663 DOI: 10.1080/10538712.2021.1937427  0.033
2020 Moore J, Fitzgerald M, Owens T, Slingsby B, Barron C, Goldberg A. Domestic Minor Sex Trafficking: A Case Series of Male Pediatric Patients. Journal of Interpersonal Violence. 886260519900323. PMID 31948332 DOI: 10.1177/0886260519900323  0.017
1935 Owens TD. Current Harmonics in Nonlinear Resistance Circuits Transactions of the American Institute of Electrical Engineers. 54: 1055-1057. DOI: 10.1109/T-AIEE.1935.5056868  0.01
Hide low-probability matches.